Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edna Mozes

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Experimental Gerontology|June 20, 2003
The effect of IL-12 on clinical and laboratory aspects of experimental SLE in young and aging miceRephael Segal, Molly Dayan, Heidy Zinger, et al.
Endocrinology|February 25, 2006
The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitopeEystein S Husebye, Eirik Bratland, Geir Bredholt, et al.
Journal of Autoimmunity|March 31, 2009
The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: the major autoantigen in autoimmune Addison's diseaseEirik Bratland, Geir Bredholt, Gunnar Mellgren, et al.
Clinical Immunology (Orlando, Fla.)|November 1, 2005
Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinaseMicha J Rapoport, Amir Sharabi, Dorit Aharoni, et al.
Human Immunology|March 13, 2009
The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patientsZev M Sthoeger, Amir Sharabi, Molly Dayan, et al.
Journal of Autoimmunity|April 7, 2009
Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expressionZev M Sthoeger, Amir Sharabi, Yair Molad, et al.
Clinical Immunology (Orlando, Fla.)|May 7, 2018
The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patientsZev Sthoeger, Amir Sharabi, Ilan Asher, et al.
The Journal of Rheumatology|January 17, 2018
Anticitrullinated Protein Antibodies Induce Inflammatory Gene Expression Profile in Peripheral Blood Cells from CCP-positive Patients with RASmadar Gertel, Gidon Karmon, Eszter Szarka, et al.
The American Journal of the Medical Sciences|January 18, 2006
High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic studyZev Sthoeger, Alexander Neiman, Daniel Elbirt, et al.
European Cytokine Network|July 15, 2006
IL-1 beta-deficient mice are resistant to induction of experimental SLEElena Voronov, Molly Dayan, Heidy Zinger, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Experimental Gerontology|June 20, 2003
The effect of IL-12 on clinical and laboratory aspects of experimental SLE in young and aging miceRephael Segal, Molly Dayan, Heidy Zinger, et al.
Endocrinology|February 25, 2006
The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitopeEystein S Husebye, Eirik Bratland, Geir Bredholt, et al.
Journal of Autoimmunity|March 31, 2009
The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: the major autoantigen in autoimmune Addison's diseaseEirik Bratland, Geir Bredholt, Gunnar Mellgren, et al.
Clinical Immunology (Orlando, Fla.)|November 1, 2005
Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinaseMicha J Rapoport, Amir Sharabi, Dorit Aharoni, et al.
Human Immunology|March 13, 2009
The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patientsZev M Sthoeger, Amir Sharabi, Molly Dayan, et al.
Journal of Autoimmunity|April 7, 2009
Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expressionZev M Sthoeger, Amir Sharabi, Yair Molad, et al.
Clinical Immunology (Orlando, Fla.)|May 7, 2018
The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patientsZev Sthoeger, Amir Sharabi, Ilan Asher, et al.
The Journal of Rheumatology|January 17, 2018
Anticitrullinated Protein Antibodies Induce Inflammatory Gene Expression Profile in Peripheral Blood Cells from CCP-positive Patients with RASmadar Gertel, Gidon Karmon, Eszter Szarka, et al.
The American Journal of the Medical Sciences|January 18, 2006
High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic studyZev Sthoeger, Alexander Neiman, Daniel Elbirt, et al.
European Cytokine Network|July 15, 2006
IL-1 beta-deficient mice are resistant to induction of experimental SLEElena Voronov, Molly Dayan, Heidy Zinger, et al.
Pageof 6